曲妥珠单抗博替康对比恩美曲妥珠单抗治疗HER2阳性晚期乳腺癌的III期随机对照试验
这项在中国57个中心开展的III期开放标签随机对照试验,纳入365例既往接受过曲妥珠单抗和紫杉烷治疗的HER2阳性不可切除/转移性乳腺癌患者,按1:1随机接受曲妥珠单抗博替康或恩美曲妥珠单抗治疗。
要点
- 曲妥珠单抗博替康较恩美曲妥珠单抗显著延长PFS(11.1 vs 4.4个月,HR 0.39)
- 客观缓解率曲妥珠单抗博替康组为76.9%,恩美曲妥珠单抗组为53.0%
- 曲妥珠单抗博替康眼部治疗相关不良事件发生率高,但多数可恢复或缓解
核心结论
- 在既往接受过曲妥珠单抗和紫杉烷治疗的HER2阳性晚期乳腺癌患者中,曲妥珠单抗博替康较恩美曲妥珠单抗显著延长无进展生存期,且具有独特的安全性特征。
研究设计与样本
- III期、开放标签、多中心随机对照试验,在中国57个中心开展,纳入365例HER2阳性不可切除/转移性乳腺癌成人患者,按1:1随机分配至曲妥珠单抗博替康组(n=182)或恩美曲妥珠单抗组(n=183)。
- 主要终点为盲态独立中心评估的PFS,采用意向性治疗分析;本次报告为预设的PFS最终分析。
主要发现
- 曲妥珠单抗博替康组客观缓解率为76.9%(95%CI 70.1-82.8),恩美曲妥珠单抗组为53.0%(95%CI 45.5-60.4)。
- 总生存数据尚未成熟,两组中位OS均未达到(HR 0.62,95%CI 0.38-1.03)。
- 曲妥珠单抗博替康组和恩美曲妥珠单抗组分别有127例(69.8%)和116例(63.7%)患者发生≥3级治疗中出现的不良事件。
- 曲妥珠单抗博替康组眼部治疗相关不良事件发生率高,但按方案定义的算法处理后多数事件恢复或缓解;肺部、血液学、肝脏和胃肠道毒性发生率低。
临床怎么用
- 对于既往接受过曲妥珠单抗和紫杉烷治疗的HER2阳性晚期乳腺癌患者,曲妥珠单抗博替康可作为恩美曲妥珠单抗的替代选择,但需关注眼部不良事件并按方案算法进行管理。
局限性
- 总生存数据尚未成熟,需更长时间随访确认生存获益。
- 研究仅在中国进行,入组人群的地域代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and efficacy of the novel human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate, trastuzumab botidotin, for the treatment of HER2-positive unresectable/metastatic breast cancer (BC). METHODS: In this phase III, open-label, multicenter trial (ClinicalTrials.gov identifier: NCT06968585), conducted at 57 centers in China, adult patients with HER2-positive, unresectable/metastatic BC who had received prior trastuzumab and a taxane were randomly assigned (1:1) to receive trastuzumab botidotin or trastuzumab emtansine. The primary end point was progression-free survival (PFS), assessed by blinded independent central review (BICR), using an intention-to-treat analysis. In a prespecified interim analysis of PFS per BICR, trastuzumab botidotin met the prespecified superiority boundary (P < .0001). We report here the prespecified final analysis of PFS. RESULTS: Between July 18, 2023, and April 26, 2024, 365 patients were randomly assigned to trastuzumab botidotin (n = 182) or trastuzumab emtansine (n = 183). At data cutoff (median follow-up, 14.9 months), trastuzumab botidotin resulted in longer PFS than trastuzumab emtansine (median, 11.1 v 4.4 months; hazard ratio [HR], 0.39 [95% CI, 0.30 to 0.51]; nominal P < .0001). Benefit was consistent across subgroups, including those defined by prior lines of anti-HER2 therapy, prior pertuzumab or anti-HER2 tyrosine kinase inhibitors, and visceral metastases. The objective response rate was 76.9% (95% CI, 70.1 to 82.8) with trastuzumab botidotin and 53.0% (95% CI, 45.5 to 60.4) with trastuzumab emtansine. Overall survival data were immature (medians not reached in either group; HR, 0.62 [95% CI, 0.38 to 1.03]). Grade ≥3 treatment-emergent adverse events occurred in 127 (69.8%) and 116 (63.7%) patients in each group, respectively. Ocular treatment-related adverse events had a high incidence with trastuzumab botidotin; however, with a protocol-defined algorithm, most events generally recovered or resolved. Trastuzumab botidotin treatment had low incidences of pulmonary, hematologic, hepatic, and GI toxicities. CONCLUSION: Among patients with HER2-positive advanced BC previously treated with trastuzumab and a taxane, trastuzumab botidotin resulted in significantly longer PFS than trastuzumab emtansine, with a distinct safety profile.
引用
- Zhang J, Ouyang Q, Zhang Q, et al. Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. J Clin Oncol. 2026. PMID: 42727044. doi:10.1200/JCO-26-00602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。